Cue Biopharma (CUE) Stock: Buy, Sell, or Hold?
CUE - Cue Biopharma, Inc.
$25.57
0.32 (1.27%)
▲
5d:
-18.59%
30d:
-5.16%
90d:
-21.31%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When CUE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CUE is down 18.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CUE is down 18.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CUE is currently trading at $25.57, which is considered oversold relative to its 30-day fair value range of $26.10 to $32.54.
Technical Outlook: Technically, CUE is in a uptrend. Immediate support is located at $23.80, while resistance sits at $41.50.
Market Sentiment: CUE scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $88.00 (+244.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CUE is in a uptrend. Immediate support is located at $23.80, while resistance sits at $41.50.
Market Sentiment: CUE scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $88.00 (+244.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$26.10 -
$32.54
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (39/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 244.2% below Wall St target ($88.00)
- WARNING: Composite score 49/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$26.10 -
$32.54
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$23.80
Resistance Level
$41.50
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.44
Wall Street Target
$88.00
(+244.2%)
Revenue Growth (YoY)
166.7%
Share & Embed Analysis
Last updated: October 03, 2026 3:20 AM ET
Data refreshes hourly during market hours. Next update: 4:20 AM
Data refreshes hourly during market hours. Next update: 4:20 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CUE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$570 | 55 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$199 | 49 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 63 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$63 | 60 BUY |
